Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Resistant ERBB2 KD mutants do not bind trastuzumab

Class:IdFailedReaction:9665232
_displayNameResistant ERBB2 KD mutants do not bind trastuzumab
_doReleaseTRUE
_timestamp2019-11-12 18:17:20
authored[InstanceEdit:9665241] Orlic-Milacic, Marija, 2019-10-30
compartment[Compartment:984] extracellular region
[Compartment:876] plasma membrane
created[InstanceEdit:9665234] Orlic-Milacic, Marija, 2019-10-30
disease[Disease:1500689] cancer
edited[InstanceEdit:9665760] Orlic-Milacic, Marija, 2019-11-01
entityFunctionalStatus[EntityFunctionalStatus:9665235] loss_of_function of ERBB2 KD mutants (trastuzumab resistant):ERBIN:HSP90:CDC37 [plasma membrane]
input[Complex:9665227] ERBB2 KD mutants (trastuzumab resistant):ERBIN:HSP90:CDC37 [plasma membrane] [Homo sapiens]
[ProteinDrug:9634466] trastuzumab [extracellular region]
isChimericFALSE
literatureReference[LiteratureReference:9646435] Activating HER2 mutations in HER2 gene amplification negative breast cancer
[LiteratureReference:9649445] High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
[LiteratureReference:9652195] Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2
[LiteratureReference:9647026] An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer
modified[InstanceEdit:9666039] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666040] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666041] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666042] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9667512] Orlic-Milacic, Marija, 2019-11-12
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
nameResistant ERBB2 KD mutants do not bind trastuzumab
normalReaction
releaseDate2019-12-10
reviewed[InstanceEdit:9662685] Kancha, Rama Krishna, 2019-09-16
reviewStatus[ReviewStatus:9821382] five stars
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9665237] R-HSA-9665232.2
summation[Summation:9665229] The following ERBB2 KD mutants are resistant to the therapeu...
(hasEvent)[Pathway:9665233] Resistance of ERBB2 KD mutants to trastuzumab [Homo sapiens]
(updatedInstance)[_UpdateTracker:9835736] Update Tracker - [FailedReaction:9665232] Resistant ERBB2 KD mutants do not bind trastuzumab - v85:[modifyText]
[Change default viewing format]
No pathways have been reviewed or authored by Resistant ERBB2 KD mutants do not bind trastuzumab (9665232)
Follow Reactome